Statera Biopharma, Inc.
STAB
$0.00
$0.000.00%
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | 73.67% | 47.20% | -46.73% | -1,725.99% | -84.20% |
| Total Depreciation and Amortization | 37.49% | 6,455.00% | 14,925.00% | 12,488.89% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -138.71% | -132.45% | -78.67% | 817.03% | 1,024.22% |
| Change in Net Operating Assets | 169.54% | 182.43% | 491.14% | 1,095.87% | -1,059.89% |
| Cash from Operations | 94.73% | 94.42% | -45.11% | -324.31% | -103.99% |
| Capital Expenditure | 100.00% | 100.00% | -38.30% | -3,130.00% | -859.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -100.00% | -100.00% | -38.30% | -3,130.00% | 26,242.08% |
| Total Debt Issued | -- | -96.64% | -- | 100.00% | -100.00% |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -88.97% | -- | -- | -- | 10.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.03% | -- | 100.00% | 100.00% |
| Cash from Financing | 5.94% | -97.23% | -234.50% | 102.98% | -87.84% |
| Foreign Exchange rate Adjustments | 2,210.00% | -- | -- | -- | -108.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.83% | -97.42% | -1,414.14% | -2,792.33% | 23.38% |